213 related articles for article (PubMed ID: 32296914)
1. Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas.
Hur JY; Kim YJ; Yoon SE; Son DS; Park WY; Kim SJ; Park D; Kim WS
Ann Hematol; 2020 Jun; 99(6):1293-1302. PubMed ID: 32296914
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma.
Chiu BC; Zhang Z; You Q; Zeng C; Stepniak E; Bracci PM; Yu K; Venkataraman G; Smith SM; He C; Zhang W
Blood Adv; 2019 Oct; 3(19):2790-2799. PubMed ID: 31570490
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.
Qi F; Cao Z; Chen B; Chai Y; Lin J; Ye J; Wei Y; Liu H; Han-Zhang H; Mao X; Feng X; Dong M
Blood Adv; 2021 Jun; 5(11):2505-2514. PubMed ID: 34047776
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
5. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
6. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma.
Niitsu N; Okabe-Kado J; Okamoto M; Takagi T; Yoshida T; Aoki S; Hirano M; Honma Y
Blood; 2001 Mar; 97(5):1202-10. PubMed ID: 11222361
[TBL] [Abstract][Full Text] [Related]
7. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.
Drake MT; Maurer MJ; Link BK; Habermann TM; Ansell SM; Micallef IN; Kelly JL; Macon WR; Nowakowski GS; Inwards DJ; Johnston PB; Singh RJ; Allmer C; Slager SL; Weiner GJ; Witzig TE; Cerhan JR
J Clin Oncol; 2010 Sep; 28(27):4191-8. PubMed ID: 20713849
[TBL] [Abstract][Full Text] [Related]
9. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
12. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer.
Lapin M; Oltedal S; Tjensvoll K; Buhl T; Smaaland R; Garresori H; Javle M; Glenjen NI; Abelseth BK; Gilje B; Nordgård O
J Transl Med; 2018 Nov; 16(1):300. PubMed ID: 30400802
[TBL] [Abstract][Full Text] [Related]
13. Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma.
Shirouchi Y; Mishima Y; Takayama T; Minowa S; Ishihara Y; Tamba M; Hirano M; Onda N; Takeuchi K; Maruyama D
Biomed Res; 2022; 43(4):99-106. PubMed ID: 35989290
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma.
Eskandari M; Manoochehrabadi S; Pashaiefar H; Zaimy MA; Ahmadvand M
Blood Res; 2019 Jun; 54(2):114-119. PubMed ID: 31309089
[TBL] [Abstract][Full Text] [Related]
15. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping.
Kambayashi S; Ono N; Tone T; Baba K; Okuda M
Vet Comp Oncol; 2024 Jun; 22(2):303-309. PubMed ID: 38287199
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
Fardella E; Zanirato G; Magni M; Caldarelli N; Chiappella A; Dodero A; Ljevar S; Orsucci L; Re A; Usai SV; Stefoni V; Castellino C; Rossi FG; Pinto A; Carniti C; Corradini P
Br J Haematol; 2024 May; 204(5):1752-1756. PubMed ID: 38176400
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival.
Lu L; Fu X; Li Z; Qiu Y; Li W; Zhou Z; Xue W; Wang Y; Jin M; Zhang M
Biochem Biophys Res Commun; 2018 Oct; 504(2):525-531. PubMed ID: 30201265
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
